Comparative Study of Kaposi's Sarcoma-Associated Herpesvirus Serological Assays Using Clinically and Serologically Defined Reference Standards and Latent Class Analysis
- 1 March 2007
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 45 (3) , 715-720
- https://doi.org/10.1128/jcm.01264-06
Abstract
Accurate determination of infection with Kaposi's sarcoma-associated herpesvirus (KSHV) has been hindered by the lack of a “gold standard” for comparison of serological assays used to estimate KSHV prevalence in serosurveys conducted in different settings. We have evaluated the performance of five in-house (developed at University College London [UCL], United Kingdom, and at the virology laboratory of the Instituto de Medicine Tropical [IMT] in Sao Paulo, Brazil) and two commercial (ABI and DIAVIR) serological assays to detect antibodies to latency-associated nuclear antigen (LANA) and to lytic KSHV antigens. We used a variety of serum samples assembled to represent populations likely to be at high, intermediate, and low risk of KSHV infection in Brazil. Composite reference standard panels were prepared based on clinical and serological parameters, against which assay performances were assessed using conventional Bayesian statistics and latent class analysis (LCA). Against the clinical reference standard, in-house immunofluorescence assays to detect anti-LANA antibodies (IFA-LANA) produced at UCL and IMT had similar performances, with sensitivities of 61% (95% confidence interval [CI], 48% to 74%) and 72% (95% CI, 58% to 83%) and specificities of 99% (95% CI, 94% to 100%) and 100% (95% CI, 96% to 100%), respectively, and only the IMT IFA-LANA was included in LCA, together with the IMT IFA-lytic and four enzyme-linked immunosorbent assays (ELISAs). The LCA indicated that the IMT whole-virus ELISA performed best (sensitivity, 87% [95% CI, 81% to 91%]; and specificity, 100% [95% CI, 98% to 100%]), confirming the results obtained with the conventional statistical approach. Commercially available ELISA-based tests yielded the lowest specificities using a spectrum of serum samples. The evaluation of KSHV serological assays is warranted before planning serosurveys in various settings.Keywords
This publication has 39 references indexed in Scilit:
- Correlates of Prevalent and Incident Kaposi’s Sarcoma–Associated Herpesvirus Infection in Men Who Have Sex with MenThe Journal of Infectious Diseases, 2002
- Highly Sensitive Assay for Human Herpesvirus 8 Antibodies That Uses a Multiple Antigenic Peptide Derived from Open Reading Frame K8.1Journal of Clinical Microbiology, 2002
- Comparison of Serologic Assays for Detection of Antibodies against Human Herpesvirus 8Clinical and Diagnostic Laboratory Immunology, 2001
- Some issues in resolution of diagnostic tests using an imperfect gold standardStatistics in Medicine, 2001
- Evaluation of the Latency?Associated Nuclear Antigen (ORF73) of Kaposi's Sarcoma–Associated Herpesvirus by Peptide Mapping and Bacterially Expressed Recombinant Western Blot AssayThe Journal of Infectious Diseases, 2000
- Identifying Human Herpesvirus 8 Infection: Performance Characteristics of Serologic AssaysJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000
- Detection of human herpesvirus 8 DNA and antibodies to latent nuclear and lytic-phase antigens in serial samples from aids patients with Kaposi’s sarcomaJournal of Clinical Virology, 2000
- Identification of Herpesvirus-Like DNA Sequences in AIDS-Sssociated Kaposi's SarcomaScience, 1994
- Estimation of test error rates, disease prevalence and relative risk from misclassified data: a reviewJournal of Clinical Epidemiology, 1988
- The value of latent class analysis in medical diagnosisStatistics in Medicine, 1986